ISIN | LU2050612402 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD |
Fund Provider |
JPMorgan Asset Management (Switzerland) LLC
Dreikönigstrasse 37 Postfach 8022 Zürich Tel. +41 (0)44 206 86 00 |
Fund Provider | JPMorgan Asset Management (Switzerland) LLC |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally. |
Peculiarities |
Current Price * | 88.39 USD | 17.01.2025 |
---|---|---|
Previous Price * | 87.27 USD | 16.01.2025 |
52 Week High * | 110.81 USD | 28.02.2024 |
52 Week Low * | 87.27 USD | 16.01.2025 |
NAV * | 88.39 USD | 17.01.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 431,797,293 | |
Unit/Share Assets *** | 125,222,367 | |
Trading Information SIX |
YTD Performance | -1.97% |
31.12.2024 - 17.01.2025
31.12.2024 17.01.2025 |
---|---|---|
YTD Performance (in CHF) | -1.65% |
31.12.2024 - 17.01.2025
31.12.2024 17.01.2025 |
1 month | -5.80% |
17.12.2024 - 17.01.2025
17.12.2024 17.01.2025 |
3 months | -13.65% |
17.10.2024 - 17.01.2025
17.10.2024 17.01.2025 |
6 months | -17.81% |
17.07.2024 - 17.01.2025
17.07.2024 17.01.2025 |
1 year | -11.51% |
17.01.2024 - 17.01.2025
17.01.2024 17.01.2025 |
2 years | -21.36% |
17.01.2023 - 17.01.2025
17.01.2023 17.01.2025 |
3 years | -32.28% |
18.01.2022 - 17.01.2025
18.01.2022 17.01.2025 |
5 years | -24.08% |
06.03.2020 - 17.01.2025
06.03.2020 17.01.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Gilead Sciences Inc | 3.55% | |
---|---|---|
Vericel Corp | 3.55% | |
Bio-Techne Corp | 3.38% | |
Novartis AG Registered Shares | 3.32% | |
PTC Therapeutics Inc | 3.31% | |
Alnylam Pharmaceuticals Inc | 3.25% | |
Bristol-Myers Squibb Co | 3.15% | |
Lonza Group Ltd | 3.12% | |
Vertex Pharmaceuticals Inc | 3.01% | |
Arcellx Inc | 3.00% | |
Last data update | 31.12.2024 |
TER *** | 0.95% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.72% |
Ongoing Charges *** | 0.93% |
SRRI ***
|
|
SRRI date *** | 31.12.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |